Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16291431 | 0.88 | SLC18A3 (0.48) | AKR1C3AKR1C1SLC18A3SIGMAR1GAA | |
| SCHEMBL10177659 | 0.80 | AKR1C3 (0.47) | AKR1C3AKR1C1SLC18A3SIGMAR1GAA | |
| SCHEMBL10895189 | 0.78 | AKR1C3 (0.61) | AKR1C3AKR1C1SLC18A3SIGMAR1GAA | |
| SCHEMBL23647061 | 0.76 | CHRNB4 (0.42) | AKR1C3AKR1C1SLC18A3SIGMAR1GAA | |
| Bicarbonate SCHEMBL7572186 | 0.74 | AKR1C3 (0.70) | AKR1C3AKR1C1SLC18A3SIGMAR1GAA | |
| SCHEMBL190417 | 0.72 | SLC18A3 (0.67) | AKR1C3AKR1C1SLC18A3SIGMAR1GAA | |
| SCHEMBL41763 | 0.72 | — | — | |
| SCHEMBL1399533 | 0.71 | SLC18A3 (0.48) | AKR1C3AKR1C1SLC18A3SIGMAR1GAA | |
| SCHEMBL10343084 | 0.71 | SLC18A3 (0.48) | AKR1C3AKR1C1SLC18A3SIGMAR1GAA | |
| SCHEMBL11027831 | 0.71 | AKR1C3 (0.42) | AKR1C3AKR1C1SLC18A3SIGMAR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266802-A1 | Tricyclic analgesics | CALVET ALAIN (US) | 2004-12-30 | — | — | US | disclosed |
| EP-1235808-A2 | TRICYCLIC ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2000075116-A2 | TRICYCLIC ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266802-A1 | Tricyclic analgesics | OPRM1, OPRL1, OPRD1 | AKR1C3 296/4885AKR1C1 442/4885SLC18A3 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.